JenaValve Marks Initial U.S. Commercial Use of Trilogy TAVR System for Aortic Regurgitation

According to a recent LinkedIn post from JenaValve Technology Inc, clinicians at Cedars-Sinai were among three U.S. sites to perform what are described as the first commercial Trilogy procedures for aortic regurgitation. The post notes that Trilogy is presented as the first and only FDA-approved transcatheter aortic valve replacement therapy for high-risk aortic regurgitation patients in the U.S.

The LinkedIn update emphasizes the scale of the unmet need, suggesting that tens of thousands of patients annually could be candidates for this therapy. It also underscores JenaValve’s intent to partner with physicians, heart teams, and hospitals nationwide, which implies an early commercialization push focused on expanding access and adoption across major cardiovascular centers.

For investors, the post points to an inflection from clinical development to initial commercial deployment in a defined niche of the structural heart market. If uptake at reference centers such as Cedars-Sinai is rapid and outcomes remain favorable, JenaValve could strengthen its competitive position in TAVR for aortic regurgitation, potentially supporting revenue growth and enhancing the company’s attractiveness as a strategic acquisition target in the cardiovascular device space.

However, the post also highlights that U.S. federal law restricts the Trilogy device to sale on the order of a physician, and it directs readers to important safety information, underscoring the regulated nature of the product. Commercial performance will likely depend on reimbursement dynamics, clinical guideline evolution, and the pace at which hospitals integrate the technology into standard practice, all of which could influence JenaValve’s long-term financial trajectory.